Table of Content
Executive Summary.….…….3
Advantage India…..….…......4
Market Overview ……..…….6
Recent trends and Strategies……...…..…16
Growth Drivers……..20
Opportunities……........….…30
Useful Information.......….….32
For updated information, please visitPharmaceuticals 3
EXECUTIVE SUMMARY
Source: 1 FICCI - Trends & Opportunities for Indian Pharma 2018, Pharmexcil, 2TechSci Research, Assocham and RNCOS
Notes: Information as per latest available data
Indian pharmaceutical industry supplies over 50 per cent of global demand for various vaccines, 40 per cent
of generic demand in the US and 25 per cent of all medicine in UK1.
Leading pharma
producer
The country’s pharmaceutical industry is expected to expand at a CAGR of 22.4 per cent over 2015–20 to
reach US$ 55 billion2. India is the second largest contributor of global biotech and pharmaceutical workforce.
The pharmaceutical sector was valued at US$ 33 billion in 2017.
Among fastest growing
industries
India accounts for 20 per cent of global exports in generics. India’s pharmaceutical exports stood at US$
17.27 billion in 2017-18 and are expected to reach US$ 20 billion by 2020. In 2018-19 these exports are
expected to cross US$ 19 billion.
One of the highest
exports
Indian healthcare sector, one of the fastest growing sectors, is expected to cross US$ 372 billion by 2022.
Rapidly growing
healthcare sector
The domestic generics market is expected to reach US$ 27.9 billion by 2020. India’s generics market has
immense potential for growth. Indian pharmaceutical companies received record 300 generic drug approvals
in USA during 2017 where the generic market is expected to reach US$ 88 billion by 2021.
High potential generics
market
By 2024-25, India’s biotech industry is estimated to increase to US$ 100 billion.
Robust growth in Biotech
industry
Pharmaceuticals
ADVANTAGE INDIA。